Gastroenterology
Providing results that matter
Through our integration with Mayo Clinic, Mayo Clinic Laboratories leads the industry in turning test results into clinical answers. We use our expertise to develop disease-specific, algorithmic-based testing approaches that provide efficient answers to each patient. Clinically reinforced and cost-effective, our tests provide insights on diagnosis, prognosis, and treatment effectivity to clarify questions and elevate patient outcomes.
Highlights
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss seasonal vaccination planning and survey findings on laboratory industry growth. Later, Leslie Donato, Ph.D., a clinical chemist at Mayo Clinic, shares how an innovative testing panel is improving the diagnosis of bile acid malabsorption.
Learn how our liver disease panel and follow-up testing led to a primary biliary cholangitis diagnosis in a 54-year-old woman.
Learn how our suite of testing reveals the cause of bile acid-induced diarrhea in a 66-year-old woman.
Find out how ileal resection accelerates bile acid malabsorption symptoms in an 80-year-old woman with Crohn’s disease.
Learn how our bile acids malabsorption panel was used to diagnose IBS-D in a 72-year-old woman.
PACE/FL - Review the latest evidence, guidelines, strategies, and testing solutions for differentiating metabolic from alcohol-related liver injury.
April 28, 2025 - Inflammatory bowel disease (IBD) is classified as either Crohn’s disease or ulcerative colitis, based on clinical presentation, endoscopic findings, histopathology, and disease distribution.
PACE/State of FL - Review known genetic predisposing factors to acute or chronic pancreatitis, as well as define who may benefit from genetic testing.
Linda Hasadsri, M.D., Ph.D., and Huong Cabral, M.S., CGC, explain how Mayo Clinic Laboratories' expanded test panel captures rarer as well as more common genetic causes of hereditary pancreatitis. That information is key to managing patients' enhanced risk for pancreatic cancer.
Clinically relevant overview of key genetic factors, testing strategies, and post-result care.
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' labile copper assay (Mayo ID: LBCS) improves upon standard blood tests for Wilson's disease. The new assay measures not just overall copper but also the fraction of copper that is bioavailable, or labile bound.
Mayo Clinic Laboratories’ newly expanded Hereditary Pancreatitis Gene Panel is transforming how clinicians diagnose and manage a complex, often elusive disease. Developed through close collaboration between lab scientists, genetic counselors, and clinicians, the test uses a whole exome sequencing backbone to analyze nine carefully selected genes with strong clinical relevance. This focused approach avoids ambiguous results while empowering early diagnosis, cancer risk assessment, and family testing. Built on a whole exome backbone with reflex capabilities, the panel represents a major step forward in precision medicine — offering clarity for patients and providers, and a platform for future genomic innovation.